Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone

Endocrinology

Volumn 146, Issue 11, 2005, Pages 4584-4596

  Koh, Amy J ^a   Demiralp, Burak ^e   Neiva, Kathleen G ^b   Hooten, Joanna ^a   Nohutcu, Rahime M ^e   Shim, Hyunsuk ^d   Datta, Nabanita S ^a   Taichman, Russell S ^a   McCauley, Laurie K ^a,c  

^a UNIVERSITY OF MICHIGAN SCHOOL OF DENTISTRY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d EMORY UNIVERSITY   (United States)

^e HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BROXURIDINE; OSTEOPROTEGERIN; PARATHYROID HORMONE; PROTEIN C FOS; PROTEIN TYROSINE KINASE; STROMAL CELL DERIVED FACTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE; BONE MARROW; CELL DIFFERENTIATION; CELL LINEAGE; CELL PROLIFERATION; CONTROLLED STUDY; GENOTYPE; HORMONE ACTION; MOUSE; NEWBORN; NONHUMAN; NUDE MOUSE; OSTEOCLAST; PRIORITY JOURNAL; VERTEBRA BODY; WILD TYPE;

ANABOLIC AGENTS; ANIMALS; APOPTOSIS; BLOTTING, NORTHERN; BONE AND BONES; BONE DEVELOPMENT; BONE TRANSPLANTATION; CALCIUM; CELL CYCLE PROTEINS; CELL DIFFERENTIATION; CELL DIVISION; CELL LINEAGE; CELLS, CULTURED; HUMANS; MICE; MICE, KNOCKOUT; MICE, NUDE; OSTEOCLASTS; OSTEOPETROSIS; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS C-FOS; SPINE; STAINING AND LABELING;

EID: 26844499571     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2005-0333     Document Type: Article

References (58)

1. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant H, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. New Engl J Med 10:1434-1441
2. Mohan S, Kutilek S, Zhang C, Shen HG, Kodama Y, Srivastava AK, Wergedal JE, Beamer WG, Baylink DJ 2000 Comparison of bone formation response to parathyroid hormone (1-34), (1-31), and (2-34) in mice. Bone 27:471-478
3. Rixon RH, Whitfield JF, Gagnon L, Isaacs RJ, Maclean S, Chakravarthy B, Durkin JP, Neugebauer W, Ross V, Sung W, Willick GE 1994 Parathyroid hormone fragments may stimulate bone growth in ovariectomized rats by activating adenylyl cyclase. J Bone Miner Res 9:1179-1189
4. Jilka RL, Weinstein RS, Bellido T, Roberson P, Parfitt AM, Manolagas SC 1999 Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104:439-446
5. Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK, Weinstein RS, O'Brien CA, Manolagas SC, Jilka RL 2003 Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 278:50259-50272
6. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. New Engl J Med 25:1207-1215
7. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. New Engl J Med 25:1216-1226
8. Delmas PD, Vergnaud P, Arlot ME, Pastoureau P, Meunier PJ, Nilssen MH 1995 The anabolic effect of human PTH (1-34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate-is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system? Bone 16:603-610
9. Clohisy JC, Scott DK, Brakenhoff KD, Quinn CO, Partridge NC 1992 Parathyroid hormone induces c-fos and c-jun messenger RNA in rat osteoblastic cells. Mol Endocrinol 6:1834-1842
10. McCauley LK, Koh AJ, Beecher CA, Rosol TJ 1997 The proto-oncogene c-fos is transcriptionally regulated by PTH and PTHrP in a cAMP-dependent manner in osteoblastic cells. Endocrinology 138:5427-5433
11. Finkel MP, Biskis BO, Jinkins PB 1966 Virus induction of osteosarcomas in mice. Science 151:698-701
12. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, Wagner EF 1994 c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266:443-448
13. Tolar J, Teitelbaum SL, Orchard PJ 2004 Osteopetrosis. New Engl J Med 30:2839-2849
14. Wang ZQ, Grigoriadis AE, Mohle-Steinlein U, Wagner EF 1991 Anovel target cell for c-fos induced oncogenesis: development of chrondrogenic tumours in embryonic stem cell chimeras. EMBO J 10:2437-2450
15. Grigoriadis AE, Wang ZQ, Wagner EF 1995 Fos and bone cell development: lessons from a nuclear oncogene. Trends Genet 11:436-441
16. Wang ZQ, Ovitt C, Grigoriadis AE, Mohle-Steinlein U, Ruther U, Wagner EF 1992 Bone and haematopoietic defects in mice lacking c-fos. Nature 360:741-745
17. Johnson RS, Spiegelman BM, Papaioannou V 1992 Pleiotropic effects of a null mutation in the c-fos proto-oncogene. Cell 71:577-586
18. Demiralp B, Chen H, Koh-Paige AJ, Keller ET, McCauley LK 2002 Anabolic effects of parathyroid hormone during endochondral bone growth are dependent on c-fos. Endocrinology 143:4038-4047
19. Soriano P, Montgomery C, Geske R, Bradley A 1991 Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64:693-702
20. Yull FE, Wei H, Jansen ED, Everhart MB, Sadikot RT, Christman JW, Blackwell T 2003 Bioluminescent detection of endotoxin effects on HIV-1 LTR-driven transcription in vivo. J Histochem Cytochem 51:741-749
21. Kalikin LM, Schneider A, Thakur MA, Fridman Y, Griffin LB, Dunn RL, Rosol TJ, Shah RB, Rehemtulla A, McCauley LK, Pienta KJ 2003 In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice. Cancer Biol Ther 2:656-660
22. Tamamura H, Omagari A, Hiramatsu K, Kanamoto T, Xu YN, Kodama E, Matsuoka M, Hattori T, Yamamoto N, Nakashima H, Otaka A, Fujii N 2001 Development specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140. Bioorg Med Chem Lett 11:1897-1902
23. Liang Z, Wu T, Lou H, Yu X, Taichman RS, Lau SK, Nie S, Umbreit J, Shim H 2004 Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Research 64:4302-4308
24. Sun YX, Schneider A, Jung Y, Wang J, Dai J, Wang J, Cook K, Osman NI, Koh-Paige AJ, Shim H, Pienta KJ, Keller ET, McCauley LK, Taichman RS 2005 Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 20:318-329
25. Koh AJ, Beecher CA, Rosol TJ, McCauley LK 1999 Cyclic AMP activation in osteoblastic cells: effects on PTH-1 receptors and osteoblastic differentiation in vitro. Endocrinology 140:3154-3162
26. Chen C, Koh AJ, Datta NS, Zhang J, Keller ET, Xiao G, Franceschi RT, D'Silva N, McCauley LK 2004 Impact of the mitogen-activated protein kinase pathway on parathyroid hormone-related protein actions in osteoblasts. J Biol Chem 279:29121-29129
27. McCauley LK, Koh AJ, Beecher CA, Cui Y, Decker JD, Francheschi RT 1995 Effects of differentiation and transforming growth factor β on PTH/PTHrP receptor mRNA levels in MC3T3-E1 cells. J Bone Miner Res 10:1243-1255
28. Pettway GJ, Schneider A, Koh AJ, Widjaja E, Morris MD, Meganck JA, Goldstein SA, McCauley LK 2005 Anabolic actions of PTH (1-34): use of a novel tissue engineering model to investigate temporal effects on bone. Bone 36:959-970
29. Datta NS, Chen C, Berry JE, McCauley LK 2005 PTHrP signaling targets cyclin D1 and induces osteoblastic cell growth arrest. J Bone Miner Res 20:1051-1064
30. Schneider A, Taboas J, McCauley LK, Krebsbach PH 2003 Skeletal homeostasis in tissue-engineered bone. J Orthop Res 21:859-864
31. Jung Y, Wang J, Schneider A, Sun YX, Koh-Paige AJ, Osman NI, McCauley LK, Taichman RS 2005 Regulation of SDF-1 (CXCL12) Production by osteoblasts in the hematopoietic microenvironment and a possible mechanisms for stem cell homing. J Bone Miner Res 19:S389
32. Boyle WJ, Simonet WS, Lacey DL 2003 Osteoclast differentiation and activation. Nature 423:337-342
33. Bellows CG, Ishida H, Aubin JE, Heersche JNM 1990 Parathyroid hormone reversibly suppresses the differentiation of osteoprogenitor cells into functional osteoblasts. Endocrinology 127:3111-3116
34. Dony C, Gruss P 1987 Proto-oncogene c-fos expression in growth regions of fetal bone and mesodermal web tissue. Nature 328:711-714
35. Angel P, Karin M 1991 The role of Jun, Fos, and the AP-1 complex in cell proliferation and transformation. Biochim Biophys Acta 1072:129-157
36. Hu E, Mueller E, Olivero S, Papaioannou V, Johnson R, Spiegelman BM 1994 Targeted disruption of the c-fos gene demonstrates c-fos-dependent and -independent pathways for gene expression stimulated by growth factors or oncogenes. EMBO J 13:3094-3103
37. Smeyne RJ, Vendrell M, Hayward M, Baker S, Miao GG, Schilling K, Robertson LM, Curran T, Morgan JI 1993 Continuous c-fos expression precedes programmed cell death in vivo. Nature 363:166-169
38. Teitelbaum SL 2000 Bone resorption by osteoclasts. Science 289:1504-1508
39. Centrella M, Horowitz MC, Wozney JM, McCarthy TL 1994 Transforming growth factor-β gene family members and bone. Endocr Rev 15:27-39
40. Yu X, Huang Y, Collin-Osdoby P, Osdoby P 2003 Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. J Bone Miner Res 18:1404-1418
41. Calvi LM, Adams GB, Welbrecht KW, Weber JM, Olson DP, Knight MC, Martin RP, Schipani E, Divieti P, Bringhurst FR, Milner LA, Kronenberg HM, Scadden DT 2003 Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425:841-846
42. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:159-161
43. Lowe C, Yondea T, Boyce BF, Chen H, Mundy GR, Soriano P 1993 Osteopetrosis in Src-deficient mice is due to an autonomous defect of osteoclasts. Proc Natl Acad Sci USA 90:4485-4489
44. Boyce B, Yoneda T, Lowe C, Soriano P, Mundy GR 1992 Requirement of pp60 c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest 90:1622-1627
45. Marzia M, Sims NA, Voit S, Migliaccio S, Taranta A, Bernardini S, Faraggiana T, Yoneda T, Mundy GR, Boyce BF, Baron R, Teti A 2000 Decreased c-src expression enhances osteoblast differentiation and bone formation. J Cell Biol 151:311-320
46. Zaidi SK, Sullivan AJ, Medina R, Ito Y, Van Wijnen AJ, Stein JL, Lian JB, Stein GS 2004 Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription. EMBO J 23:790-799
47. Fleisch H, Reszka A, Rodan G, Rogers M 2002 Bisphosphonates: mechanisms of action. In: Bilezikian JP, Raisz LG, Rodan G, eds. Principles of bone biology. San Diego: Academic Press; 1361-1385
48. Hodsman AB, Fraher LJ, Watson PH, Ostbye T, Stitt LW, Adachi JD, Taves DH, Drost D 1997 A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis. J Clin Endocrinal Metab 82:620-628
49. Kostenuik PJ, Capparelli C, Morony S, Adamu S, Shimamoto G, Shen V, Lacey DL, Dunstan CR 2001 OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 142:4295-4304
50. Zhu J, Emerson SG 2004 A new bone to pick: osteoblasts and the haematopoietic stem-cell niche. Bioessays 26:595-599
51. Taichman RS 2005 Blood and bone: two tissues whose fates are intertwined to create the hematopoietic stem cell niche. Blood 105:2631-2639
52. Phan T, Han R, Davey T, Smut V, Zheng MH, Xu J 2004 Identification and functional characterization of a novel osteoclast-derived osteoblastic factor (ODOF). J Bone Miner Res 19:S37
53. Zhao C, Irie N, Shimoda K, Miyamoto T, Nishiwaki T, Ishikawa H, Suda T 2004 Bidirectional signaling by Ephrinb2-EphB4 coordinates osteoclast and osteoblast functions to enhance bone formation. J Bone Miner Res 19:S14
54. Martin TJ 2004 Does bone resorption inhibition affect the anabolic response to parathryoid hormone? Trends Endocrinol Metab 15:49-50
55. Karsdal MA, Henriksen K, Sorensen MG, Gram J, Schaller S, Dziegiel MH, Heegaard AM, Christophersen P, Martin TJ, Christiansen C, Bollerslev J 2005 Acidification of the osteoclastic resorption compartment provides insight into the coupling of bone formation to bone resorption. Am J Pathol 166:467-476
56. Rouleau MF, Mitchell J, Goltzman D 1998 In vivo distribution of parathyroid hormone receptors in bone: evidence that a predominant osseous target cell is not the mature osteoblast. Endocrinology 123:187-191
57. Andreassen TT, Willick GE, Morley P, Whitfield JF 2004 Treatment with parathyroid hormone hPTH(1-34), hPTH(1-31), and monocyclic hPTH(1-31) enhances fracture strength and callus amount after withdrawal fracture strength and callus mechanical quality continue to increase. Calcif Tissue Int 74:351-356
58. Chen H, Frankenberg L, Goldstein SA, McCauley LK 2003 The combination of local and systemic PTH enhances fracture healing. Clin Orthop Relat Res 416:291-302